What clotting factor tests does an ophthalmologist typically order before intra‑ocular or ocular‑surface surgery?

Ophthalmologists Do Not Routinely Order Clotting Factor Studies Before Ocular Surgery

Routine preoperative coagulation testing (PT, aPTT, platelet count, or clotting factor studies) is not indicated for ophthalmologic surgery, including cataract, glaucoma, and most other intraocular procedures 1, 2.

Evidence-Based Rationale

The 2022 American Academy of Ophthalmology Cataract Preferred Practice Pattern explicitly states that routine preoperative laboratory testing is not indicated, based on a very large prospective randomized clinical trial demonstrating that routine medical testing did not reduce perioperative morbidity and mortality 1. This applies specifically to cataract surgery, where over 19,000 patients showed no difference in outcomes between those who underwent preoperative testing versus no testing 2.

When Coagulation Assessment IS Warranted

Testing should be directed and selective, reserved only for:

History-Based Indications

• Personal history of spontaneous bruising or excessive surgical bleeding
• Family history of known heritable coagulopathy (e.g., von Willebrand disease, hemophilia)
• Medical conditions associated with impaired hemostasis:
  • Liver disease
  • Diseases of hematopoiesis
  • Renal insufficiency requiring dialysis

Medication-Related Indications

• Patients currently taking anticoagulants (warfarin, DOACs) where verification of therapeutic range may be needed
• This is NOT for routine discontinuation, but rather to confirm appropriate dosing 2, 3

Critical Pitfall to Avoid

Do not order coagulation studies to justify stopping anticoagulation or antiplatelet therapy. The evidence strongly demonstrates that:

• Continuing antiplatelet agents (aspirin, clopidogrel) through cataract surgery causes only minor increases in subconjunctival hemorrhage (16.5% vs 10.8%), with no impact on visual outcomes or serious complications 4
• Continuing warfarin and DOACs during phacoemulsification is safe when INR is therapeutic 5, 6
• The thromboembolic risk from discontinuing anticoagulation substantially exceeds the risk of significant ocular hemorrhage 6

Practical Algorithm

1. Obtain bleeding history from all surgical patients 2

   • Ask specifically about: easy bruising, prolonged bleeding from minor cuts, excessive bleeding after dental procedures, heavy menstrual bleeding, family history of bleeding disorders

2. If bleeding history is normal AND no high-risk medical conditions:

   • No coagulation testing needed
   • Continue all antiplatelet and anticoagulant medications through surgery 4, 5, 6

3. If abnormal bleeding history OR high-risk conditions present:

   • Consider directed coagulation testing (PT/INR, aPTT, platelet count)
   • Specific factor assays only if inherited coagulopathy suspected 2

4. For patients on anticoagulation:

   • Verify INR is within therapeutic range if on warfarin
   • Continue medication through most ophthalmic procedures 7, 6
   • Consult cardiology/hematology only for complex cases or sharp needle anesthesia 7

The key principle: routine screening coagulation panels have no role in preoperative ophthalmologic assessment 1, 2.